Dealmakers face tariff turmoil; Archimed, Nordic Capital, Patricia Industries bet on clinical research tech

Some takeaways from an SS&C Intralinks report on how tariffs may affect deal activity in the second quarter of 2025; a conversation with with Michelle Mantine, partner at law firm Reed Smith, about how the FTC's decision to retain 2023 merger guidelines may affect healthcare investing; the demand for clinical research technologies.

CommentaryPE Hub Wire